Together, these results suggest that the presence of T cells reactive to tumor-initiating, persistent neoepitopes, like mutant KRAS, in tumors may associate with better patient outcome and liver-adverse metastatic disease, but selective clonal expansion in lung cohort or low pORG tumors associated with their better outcome does not often involve expansion of these clones; however, further discovery of additional putative mutant KRAS CDR3s and HLA tumor-matching is required to validate these hypotheses. This evidence concerns the gene KRAS and metastatic neoplasm.